Analysts predict that West Pharmaceutical Services Inc. (NYSE:WST) will post earnings of $0.72 per share for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for West Pharmaceutical Services’ earnings. The highest EPS estimate is $0.73 and the lowest is $0.71. West Pharmaceutical Services posted earnings per share of $0.67 during the same quarter last year, which would indicate a positive year over year growth rate of 7.5%. The company is expected to announce its next earnings results on Thursday, October 25th.

On average, analysts expect that West Pharmaceutical Services will report full year earnings of $2.82 per share for the current fiscal year, with EPS estimates ranging from $2.80 to $2.84. For the next financial year, analysts anticipate that the firm will post earnings of $3.22 per share, with EPS estimates ranging from $3.06 to $3.35. Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for West Pharmaceutical Services.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, July 26th. The medical instruments supplier reported $0.70 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.67 by $0.03. The firm had revenue of $447.50 million during the quarter, compared to analysts’ expectations of $422.57 million. West Pharmaceutical Services had a return on equity of 15.38% and a net margin of 8.99%. West Pharmaceutical Services’s quarterly revenue was up 12.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.66 EPS.

WST has been the topic of a number of recent analyst reports. ValuEngine raised West Pharmaceutical Services from a “sell” rating to a “hold” rating in a research report on Tuesday, June 12th. Zacks Investment Research lowered West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research report on Tuesday, July 17th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $108.33.

Shares of WST traded down $0.31 during trading on Friday, reaching $116.27. The company’s stock had a trading volume of 229,106 shares, compared to its average volume of 269,934. West Pharmaceutical Services has a twelve month low of $82.74 and a twelve month high of $118.05. The firm has a market cap of $8.57 billion, a price-to-earnings ratio of 41.82, a PEG ratio of 3.96 and a beta of 1.20. The company has a quick ratio of 1.94, a current ratio of 2.67 and a debt-to-equity ratio of 0.15.

In other West Pharmaceutical Services news, VP Daniel Malone sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, June 11th. The stock was sold at an average price of $97.24, for a total value of $486,200.00. Following the transaction, the vice president now directly owns 34,020 shares of the company’s stock, valued at approximately $3,308,104.80. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Karen Flynn sold 20,458 shares of the company’s stock in a transaction that occurred on Tuesday, August 7th. The shares were sold at an average price of $116.23, for a total value of $2,377,833.34. Following the completion of the transaction, the senior vice president now directly owns 31,051 shares in the company, valued at $3,609,057.73. The disclosure for this sale can be found here. Corporate insiders own 1.90% of the company’s stock.

Hedge funds have recently bought and sold shares of the stock. Integrated Investment Consultants LLC acquired a new stake in shares of West Pharmaceutical Services during the 2nd quarter valued at approximately $155,000. Toronto Dominion Bank raised its position in shares of West Pharmaceutical Services by 815.7% during the 1st quarter. Toronto Dominion Bank now owns 1,923 shares of the medical instruments supplier’s stock valued at $170,000 after acquiring an additional 1,713 shares in the last quarter. Whittier Trust Co. of Nevada Inc. raised its position in shares of West Pharmaceutical Services by 53.0% during the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 1,994 shares of the medical instruments supplier’s stock valued at $176,000 after acquiring an additional 691 shares in the last quarter. First Allied Advisory Services Inc. acquired a new stake in shares of West Pharmaceutical Services during the 2nd quarter valued at approximately $200,000. Finally, Alps Advisors Inc. acquired a new stake in shares of West Pharmaceutical Services during the 2nd quarter valued at approximately $206,000. 94.71% of the stock is currently owned by institutional investors and hedge funds.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

Further Reading: How Do I Invest in Dividend Stocks

Get a free copy of the Zacks research report on West Pharmaceutical Services (WST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.